Medical Therapy of Endometriosis

David L. Olive

doi:10.1055/s-2003-41327

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2003; 21(2): 209-222
DOI: 10.1055/s-2003-41327

Medical Therapy of Endometriosis

David L. Olive

Department of Obstetrics Gynecology, University of Wisconsin Medical School Madison, Wisconsin

Abstract

ABSTRACT

The medical treatment of endometriosis is a critical aspect of the therapeutic approach to this disease. Past methods have been based upon systemic hormonal alterations, resulting in suppression of this estrogen-responsive disorder. Treatments such as danazol, progestogens, oral contraceptives, GnRH-agonists, and gestrinone achieve their effects upon endometriosis via this method. However, with a growing understanding of the pathogenesis of this disease, more precise molecular targets for treatment have been identified. Thus, a series of newer agents are under development and hold the potential of greater efficacy and flexibility than traditional treatments. This review analyzes the available and experimental medical treatments of endometriosis, their utility in the treatment of pain and infertility, and their role in the future.

KEYWORDS

Endometriosis - medical therapy - infertility - pelvic pain - review

Full Text

References

REFERENCES

1 Goebel R, Rjosk H K. Laboratory and clinical studies with the new antigonadotropin, danazol (Abstract). Acta Endocrinol . 1977; 85 (suppl 212) 134
2 Floyd W S. Danazol: endocrine and endometrial effects. Int J Fertil . 1980; 25 75-80
3 Barbieri R L, Canick J A, Makris A. et al . Danazol inhibits steroidogenesis. Fertil Steril . 1977; 28 809-813
4 McGinley R, Casey J H. Analysis of progesterone in unextracted serum: a method using danazol [17α-pregn-4-en-20-yno(2,3-d) osoxazol-17-ol] a blocker of steroid binding to proteins. Steroids . 1979; 33 127-138
5 Buttram Jr C V, Belue J B, Reiter R. Interim report of a study of danazol for the treatment of endometriosis. Fertil Steril . 1982; 37 478-483
6 Alvarado R G, Liu J Y, Zwolak R M. Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg . 2001; 34 1123-1126
7 Vercellini P, Tresid L, Panazza S. et al . Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study. Fertil Steril . 1994; 62 1136-42
8 Janicki T I. Treatment of the pelvic pain associated with endometriosis using danazol vaginal suppositories. Two year followup. Fertil Steril . 2002; 77 S52
9 Igarashi M, Iizuka M, Abe Y, Ibuki Y. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod . 1998; 13 1952-1956
10 Bruner K L, Eisenberg E, Gorstein F, Osteen K G. Progesterone and transforming growth factor-beta coordinately regulate suppression of endometrial matrix metalloproteinases in a model of experimental endometriosis. Steroids . 1999; 64 648-653
11 Olive D L. Medical treatment: alternatives to danazol. In: Schenken RS, ed. Endometriosis: Contemporary Concepts in Clinical Management Philadelphia: JB Lippincott 1989: 189-211
12 Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med . 1999; 43 24-27
13 Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril . 2001; 75 485-488
14 Lau T M, Affandi B, Rogers P AW. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. Mol Hum Reprod . 1998; 5 57-63
15 Hamblen E C. Androgen treatment of women. South Med J . 1957; 50 743
16 Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med . 1981; 304 560-563
17 Fahraeus L, Sydsjo A, Wallentin L. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril . 1986; 45 503-506
18 Andrews M C, Andrews W C, Strauss A F. Effects of progestin-induced pseudopregnancy on endometriosis; clinical and microscopic studies. Am J Obstet Gynecol . 1959; 78 776
19 Scott R B, Wharton Jr R L. The effect of estrone and progesterone on the growth of experimental endometriosis in rhesus monkeys. Am J Obstet Gynecol . 1957; 74 852
20 Noble A D, Letchworth A T. Medical treatment of endometriosis: a comparative trial. Postgrad Med J . 1979; 55 (suppl 5) 37-39
21 Meresman G F, Auge L, Barano R I. et al . Oral contraceptives treatment suppresses proliferation and enhances apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril . 2001; 76 S47-S48
22 Sharpe-Timms K L, Zimmer R L, Jolliff W J. et al . Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation. Fertil Steril . 1998; 69 916-923
23 Dmowski W P. The role of medical management in the treatment of endometriosis. In: Nezhat CR, Berger GS, Nezhat FR, et al, eds. Endometriosis: Advanced Management and Surgical Techniques New York: Springer-Verlag 1995: 229-240
24 Barbieri R L. Endometriosis and the estrogen threshold theory, relation to surgical and medical treatment. J Reprod Med . 1998; 43 287-292
25 Hurst B S, Gardner S C, Tucker K E, Awoniyi C A, Schlaff W D. Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. JSLS . 2000; 4 97-101
26 Cornillie F J, Brosens I A, Vasquez G, Riphogen I. Histologic and ultrastructural changes in human endometriotic implants treated with the antiprogesterone steroid ethylnorgestrienone (gestrinone) during 2 months. Int J Gynecol Pathol . 1986; 5 95-109
27 Robyn C, Delogne-Desnoeck J, Bourdoux P, Copinschi G. Endocrine effects of gestrinone. In: Raynaud J-P, Ojasoot T, Martini L, eds. Medical Management of Endometriosis New York: Raven Press 1984: 207
28 Tjaden B, Galetto D, Woodruff J D, Rock J A. Time-related effects of RU486 treatment in experimentally induced endometriosis in the rat. Fertil Steril . 1993; 59 437-440
29 Kettel L M, Murphy A A, Mortola J F. et al . Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril . 1991; 56 402-407
30 Jones R C. The effect of a luteinizing hormone-releasing hormone antagonist on experimental endometriosis in the rat. Acta Endocrinol (Copenh) . 1987; 114 379-382
31 Woolley J M, De Paoli M A, Gray M E, Martha P M. Reductions in health related quality of life in women with endometriosis. Seventh Biennial World Congress of Endometriosis; May 14-17, 2000; London. Abst
32 Bulun S E, Zeitoun K M, Takayama K, Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update . 2000; 6 413-418
33 Yano S, Ikegami Y, Nakao K. Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung . 1996; 46 192-195
34 D'Hooghe T M, Cuneo S, Nugent N. et al . Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons; a prospective, randomized, placebo and drug controlled study. Fertil Steril . 2001; 76 S1
35 Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod . 1998; 13 1686-1690
36 Fasciani A, D'Ambrogio G, Bocci G. et al . High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Mol Hum Reprod . 2000; 6 50-54
37 Mahnke J L, Dawood M Y, Huang J C. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril . 2000; 73 166-170
38 Barcz E, Kaminski P, Marianowski L. VEGF concentration in peritoneal fluid in patients with endometriosis. Gynekol Pol . 2001; 72 442-448
39 Levine Z, Efstathiou J A, Sampson D A. et al . Angiogenesis inhibitors suppress endometriosis in a murine model. J Soc Gynecol Investig . 2002; 9 264a
40 Mori T, Yamasaki S, Masui F. et al . Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med . 2001; 226 429-433
41 Steinleitner A, Lambert H, Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril . 1991; 55 26-31
42 Steinleitner A, Lambert H, Suarez M. Immunomodulation in the treatment of endometriosis-associated subfertility: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model. Fertil Steril . 1991; 56 975-979
43 Physicians' Desk Reference Montvale, NJ: Medical Economics Company . 2002: 784
44 Olive D L, Pritts E A, Morales A J. Evidence-based medicine: study design for evaluation and treatment. J Am Assoc Gynecol Laparosc . 1998; 5 75-82
45 Hughes E G. Systematic literature review and meta-analysis. Semin Reprod Endocrinol . 1996; 14 161-169
46 Cooke I D, Thomas E J. The medical treatment of mild endometriosis. Acta Obstet Gynecol Scand Suppl . 1989; 150 27-30
47 D'Hooghe T M, Bambra C S, Isahakia M, Koninckx P R. Evolution of spontaneous endometriosis in the baboon (Papio anubis, Papio cynocephalus) over a 12-month period. Fertil Steril. 1992; 58 409-412
48 Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C. Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. Obstet Gynecol . 2001; 98 258-264
49 Kauppila A, Puolakka J, Ylikorkala O. Prostaglandin biosynthesis inhibitors and endometriosis. Prostaglandins . 1979; 18 655-661
50 Dmowski W P, Cohen M R. Treatment of endometriosis with an antigonadotropin, danazol: A laparoscopic and histologic evaluation. Obstet Gynecol . 1975; 46 147-154
51 Barbieri R L, Evans S, Kistner R W. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril . 1982; 37 737-746
52 Doberl A, Jeppsson S, Rannevik G. Effect of danazol on serum concentrations of pituitary gonadotropins in post-menopausal women. Acta Obstet Gynecol Scand . 1984; 123(suppl) 95-98
53 Buttram Jr C V, Reiter R C, Ward S. Treatment of endometriosis with danazol: report of a six-year prospective study. Fertil Steril . 1985; 43 353-360
54 Henzl M R, Corson S L, Moghissi K. et al . Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med . 1988; 318 485-489
55 Telimaa S, Puolakka J, Ronnberg L, Kaupilla A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol . 1987; 1 13-23
56 Fedele L, Bianchi S, Viezzoli T, Arcaini L, Cendiani G B. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril . 1989; 51 781-785
57 Worthington M, Irvine L M, Crook D. et al . A randomized comparative study of the metabolic effects of two regimens of gestrinone in the treatment of endometriosis. Fertil Steril . 1993; 59 522-526
58 Hornstein M D, Gleason R E, Barbieri R L. A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. Fertil Steril . 1990; 53 237-241
59 Cedars M I, Lu J K, Meldrum D R, Judd H L. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol . 1990; 75 641-645
60 Surrey E S, Gambone J C, Lu J K, Judd H L. Fertil Steril . 1990; 53 620-626
61 Henzl M R, Corson S L, Moghissi K. et al . Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med . 1998; 318 485-489
62 Surrey E S, Voigt B, Fournet N, Judd H L. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low dose norethindrone “add-back” therapy. Fertil Steril . 1995; 63 747-755
63 Bayer S R, Seibel M M. Medical treatment: danazol. In: Schenkel RS, ed. Endometriosis: Contemporary Concepts in Clinical Management Philadelphia: JB Lippincott 1989: 169-187
64 Miller J D, Shaw R W, Casper R F. et al . Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin-releasing hormone agonist. Fertil Steril . 1998; 70 293-296
65 Regidor P A, Regidor M, Schmidt M. et al . Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol . 2001; 15 202-209
66 Vercellini P, Trespidi L, Colombo A. et al . A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril . 1993; 60 75-79
67 Frontino G, Vercellini P, De Giorgi O. et al . Continuous use of oral contraceptive (OC) for endometriosis-associated recurrent dysmenorrhea not responding to cyclic pill regimen. Fertil Steril . 2002; 77 S23-S24
68 Dlugi A M, Miller J D, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril . 1990; 54 419-427
69 Anonymous. Goserelin depot versus danazol in the treatment of endometriosis: the Australian/New Zealand experience. Aust N Z J Obstet Gynaecol . 1996; 31 55-60
70 Chang S P, Ng H T. A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chin Med J (Taipei) . 1996; 57 431-437
71 Cirkel U, Oochs H, Schneider H PG. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol . 1995; 59 61-69
72 Crosignani P G, Gastaldi A, Lombardi P L. et al . Leuprorelin acetate depot versus danazol in the treatment of endometriosis: results of an open multicentre trial. Clin Ther . 1992; 14 (suppl A) 29-36
73 Dmowski W P, Radwanska E, Binor Z, Tummon I, Pepping P. Ovarian suppression induced with buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril . 1989; 51 395-400
74 Fraser I S, Shearman R P, Jansen R P, Sutherland P D. A comparative treatment trial of endometriosis using the gonadotropin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust NZ J Obstet Gynaecol . 1991; 31 158-163
75 Adamson G D, Kwei L, Edgren R A. Pain of endometriosis: effects of nafarelin and danazol therapy. Int J Fertil Med Stud . 1994; 39 215-217
76 Wheeler J M, Knittle J D, Miller J D. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am J Obstet Gynecol . 1992; 167 1367-1371
77 Dawood M Y, Ramos J, Khan-Dawood F S. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril . 1995; 63 1177-1183
78 The Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil Steril . 1992; 57 514-522
79 Rolland R, van der Heijden F P. Nafarelin versus danazol in the treatment of endometriosis. Am J Obstet Gynecol . 1990; 162 586-588
80 Kennedy S H, Williams I A, Brodribb J, Barlow D H, Shaw R W. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril . 1990; 53 998-1003
81 Rock J A. A multicenter comparison of GnRH agonist (Zoladex) and danazol in the treatment of endometriosis. Fertil Steril . 1991; 56 S49
82 Shaw R W. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. Fertil Steril . 1992; 58 265-272
83 Prentice A, Deery A, Goldbeck-Wood S, Farquhar C, Smith S. Gonadotropin-releasing hormone analogues for pain associated with endometriosis (Cochrane review). In: The Cochrane Library, Issue 3 Oxford: Update Software 1999
84 Ling F W. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Obstet Gynecol . 1999; 93 51-58
85 Surrey E, Judd H. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab . 1992; 75 558-563
86 Makarainen L, Ronneberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side-effects of gonadotropin-releasing hormone agonists without changing its efficacy in endometriosis. Fertil Steril . 1996; 65 29-34
87 Tabkin O, Yakinoghe A H, Kucuk S. et al . Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril . 1997; 67 40-45
88 Edmonds D, Howell R. Can hormone replacement therapy by used during medical therapy of endometriosis?. Br J Obstet Gynaecol . 1994; 101 24-26
89 Kiiholma P, Korhonen M, Tuimala R, Korhonen M, Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogens add-back therapy in the treatment of endometriosis. Fertil Steril . 1995; 64 903-908
90 Moghissi K S, Schlaff W D, Olive D L, Skinner M A, Yin H. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril . 1998; 69 1056-1062
91 Hornstein M D, Surrey E S, Weisberg G W, Casino L A, Lupron Add-Back Study Group. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol . 1998; 91 16-24
92 Lee P I, Yoon J B, Joo K Y. et al . Gonadotrophin releasing hormone agonist (GnRHa)-Zoladex (Goserelin) and hormonal add-back therapy in endometriosis: a 12 month study. Fertil Steril . 2002; 77 S23
93 The Gestrinone Italian Study Group. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter randomised, double-blind study. Fertil Steril . 1996; 66 911-919
94 Bayer S R, Seibel M M, Saffan D S, Berger M J, Taymor M L. Efficacy of danazol treatment for minimal endometriosis in infertile women: a prospective, randomized study. J Reprod Med . 1988; 33 179-183
95 Telimaa S. Danazol and medroxyprogesterone acetate inefficacious in the treatment of infertility in endometriosis. Fertil Steril . 1988; 50 872-875
96 Harrison R F, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril . 2000; 74 24-30
97 Fedele L, Parazzini F, Radici E. et al . Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: a randomized clinical trial. Am J Obstet Gynecol . 1992; 166 1345-1350
98 Thomas E, Cooke I. Successful treatment of asymptomatic endometriosis: does it benefit infertile women?. BMJ . 1987; 294 1117-1119
99 Hughes E, Ferorkow D, Collins J, Vandekerckhone P. Ovulation suppression for endometriosis (Cochrane review). In: The Cochrane Library, Issue 1 Oxford: Update Software 2000
100 Balasch J, Creus M, Fabregues F. et al . Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod . 1997; 12 2046-2050
101 Audebert A, Descampes P, Marret H. Pre or postoperative medical treatment with nafarelin in stage III-IV endometriosis: a French multicentered study. Eur J Obstet Gynecol Reprod Biol . 1998; 79 145-148
102 Bianchi S, Busacca M, Agnoli B. Effects of three month therapy with danazol after laparoscopic surgery for stage III-IV endometriosis: a randomized study. Hum Reprod . 1999; 14 1335-1337
103 Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynaecol Endocrinol . 1987; 1 363-371
104 Parazzini F, Fedele L, Busacca M. et al . Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol . 1994; 171 1205-1207
105 Hornstein M D, Hemmings R, Yuzpe A A, Heinrichs W L. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril . 1997; 68 860-864
106 Vercellini P, Crosignani P G, Fedini R. A gonadotropin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol . 1999; 106 672-677
107 Muzii L, Marana R, Caruana P. et al . Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial. Am J Obstet Gynecol . 2000; 183 588-592
108 Frontino G, Vercellini P, De Giorgi O. et al . Levonorgestrel-releasing intrauterine device (Lng-IUD) versus expectant management after conservative surgery for symptomatic endometriosis. A pilot study. Fertil Steril . 2002; 77 S25-S26
109 Morgante G, Ditto A, La Marca A, De Leo V. Low dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis. Hum Reprod . 1999; 14 2371-2374
110 Alvarez-Gil L, Fuentes V. Raloxifene and endometriosis. Fertil Steril . 2002; 77 S37